{
  "lastUpdated": "2026-02-07T23:00:00.480Z",
  "count": 27,
  "items": [
    {
      "id": "aHR0cHM6Ly90aGVu",
      "title": "Medical devices & technology",
      "company": "Johnson & Johnson",
      "category": "General News",
      "summary": "Medical devices & technology",
      "publishedDate": "2026-02-07T23:00:00.479Z",
      "url": "https://thenext.jnjmedtech.com/",
      "tags": []
    },
    {
      "id": "aHR0cHM6Ly90aGVu",
      "title": "Cardiovascular",
      "company": "Johnson & Johnson",
      "category": "General News",
      "summary": "Cardiovascular",
      "publishedDate": "2026-02-07T23:00:00.479Z",
      "url": "https://thenext.jnjmedtech.com/healthcare-area/cardiovascular",
      "tags": [
        "Cardiovascular"
      ]
    },
    {
      "id": "aHR0cHM6Ly90aGVu",
      "title": "Orthopaedics",
      "company": "Johnson & Johnson",
      "category": "General News",
      "summary": "Orthopaedics",
      "publishedDate": "2026-02-07T23:00:00.479Z",
      "url": "https://thenext.jnjmedtech.com/healthcare-area/orthopaedics",
      "tags": []
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "Medicines & therapies",
      "company": "Johnson & Johnson",
      "category": "General News",
      "summary": "Medicines & therapies",
      "publishedDate": "2026-02-07T23:00:00.478Z",
      "url": "https://www.jnj.com/innovativemedicine",
      "tags": []
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "Neuroscience",
      "company": "Johnson & Johnson",
      "category": "General News",
      "summary": "Neuroscience",
      "publishedDate": "2026-02-07T23:00:00.478Z",
      "url": "https://www.jnj.com/innovativemedicine/neuroscience",
      "tags": []
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "Cardiopulmonary",
      "company": "Johnson & Johnson",
      "category": "General News",
      "summary": "Cardiopulmonary",
      "publishedDate": "2026-02-07T23:00:00.478Z",
      "url": "https://www.jnj.com/innovativemedicine/cardiopulmonary",
      "tags": [
        "Cardiovascular"
      ]
    },
    {
      "id": "Iw==",
      "title": "locationPlaceholder",
      "company": "Johnson & Johnson",
      "category": "General News",
      "summary": "locationPlaceholder",
      "publishedDate": "2026-02-07T23:00:00.477Z",
      "url": "https://www.jnj.com#",
      "tags": []
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "Medicines & therapies",
      "company": "Johnson & Johnson",
      "category": "General News",
      "summary": "Medicines & therapies",
      "publishedDate": "2026-02-07T23:00:00.476Z",
      "url": "https://www.jnj.com/innovativemedicine/",
      "tags": []
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "Discover J&J",
      "company": "Johnson & Johnson",
      "category": "General News",
      "summary": "Discover J&J",
      "publishedDate": "2026-02-07T23:00:00.473Z",
      "url": "https://www.jnj.com/",
      "tags": []
    },
    {
      "id": "aHR0cHM6Ly9uZXdz",
      "title": "AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results",
      "company": "AbbVie",
      "category": "Financial",
      "summary": "AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results",
      "publishedDate": "2026-02-07T23:00:00.326Z",
      "url": "https://news.abbvie.com/email-alerts?type=2",
      "tags": []
    },
    {
      "id": "L21lZGlhLWNlbnRy",
      "title": "Contacts\n                View global media contacts",
      "company": "AstraZeneca",
      "category": "General News",
      "summary": "View global media contacts",
      "publishedDate": "2026-02-07T23:00:00.177Z",
      "url": "https://www.astrazeneca.com/media-centre/contacts.html",
      "tags": []
    },
    {
      "id": "I3Byb21vdGlsZXN2",
      "title": "Subscribe\n                Sign up to receive our news alerts",
      "company": "AstraZeneca",
      "category": "General News",
      "summary": "Sign up to receive our news alerts",
      "publishedDate": "2026-02-07T23:00:00.177Z",
      "url": "https://www.astrazeneca.com#promotilesv2-content-astraz-media-centre-press-releases-jcr-content-par-contentwrapper_1232730866-wrapperPar-promotilesv2-signup",
      "tags": []
    },
    {
      "id": "L21lZGlhLWNlbnRy",
      "title": "Social Media Community Guidelines",
      "company": "AstraZeneca",
      "category": "General News",
      "summary": "Social Media Community Guidelines",
      "publishedDate": "2026-02-07T23:00:00.177Z",
      "url": "https://www.astrazeneca.com/media-centre/social-media-community-guidelines.html",
      "tags": []
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "Feature\n                                          Sustainable science",
      "company": "AstraZeneca",
      "category": "General News",
      "summary": "Feature Sustainable science",
      "publishedDate": "2026-02-07T23:00:00.175Z",
      "url": "https://www.astrazeneca.com/media-centre/articles/sustainable-science-lab-to-patient.html",
      "tags": [
        "Digital Health"
      ]
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "Media library & contacts",
      "company": "Merck",
      "category": "General News",
      "summary": "Media library & contacts",
      "publishedDate": "2026-02-07T23:00:00.121Z",
      "url": "https://www.merck.com/media/media-library/",
      "tags": []
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "Company fact sheet",
      "company": "Merck",
      "category": "General News",
      "summary": "Company fact sheet",
      "publishedDate": "2026-02-07T23:00:00.121Z",
      "url": "https://www.merck.com/media/company-fact-sheet/",
      "tags": []
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need",
      "company": "Pfizer",
      "category": "FDA Approval",
      "summary": "FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need Anonymous (not verified) Fri, 02/06/2026 - 06:4...",
      "publishedDate": "Fri, 06 Feb 2026 11:45:00 +0000",
      "url": "https://www.pfizer.com/news/press-release/press-release-detail/fda-grants-priority-review-hympavzir-marstacimab-sbla",
      "tags": [
        "Cardiovascular",
        "Vaccines",
        "Rare Disease"
      ]
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans",
      "company": "Pfizer",
      "category": "Clinical Trial",
      "summary": "Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans Anonymous (not verified) Thu, 02/05/2026 - 19:09 Pfizer Press release Corporate View pdf copy Copy to clip...",
      "publishedDate": "Fri, 06 Feb 2026 00:09:00 +0000",
      "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-launches-cost-savings-program-trumprx-lowering-drug",
      "tags": [
        "Vaccines",
        "Rare Disease",
        "COVID-19"
      ]
    },
    {
      "id": "aHR0cHM6Ly9uZXdz",
      "title": "AbbVie Reports Full-Year and Fourth-Quarter 2025 Financial Results",
      "company": "AbbVie",
      "category": "Financial",
      "summary": "Reports Full-Year Diluted EPS of $2.36 on a GAAP Basis, a Decrease of 1.3 Percent; Adjusted Diluted EPS of $10.00, a Decrease of 1.2 Percent; These Results Include an Unfavorable Impact of $2.76...",
      "publishedDate": "February 04, 2026",
      "url": "https://news.abbvie.com/email-alerts",
      "tags": []
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance",
      "company": "Pfizer",
      "category": "FDA Approval",
      "summary": "Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance Anonymous (not verified) Tue, 02/03/2026 - 06:45 Pfizer Press release View pdf copy Copy to clipboard Open in tab .q4default .bw...",
      "publishedDate": "Tue, 03 Feb 2026 11:45:00 +0000",
      "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reports-solid-full-year-2025-results-and-reaffirms",
      "tags": [
        "Oncology",
        "Cardiovascular",
        "Diabetes"
      ]
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial",
      "company": "Pfizer",
      "category": "FDA Approval",
      "summary": "Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial Anonymous (not verified) Tue, 02/03/2026 - 06:40 Pfizer Press release Resear...",
      "publishedDate": "Tue, 03 Feb 2026 11:40:00 +0000",
      "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizers-ultra-long-acting-injectable-glp-1-ra-shows-robust",
      "tags": [
        "Diabetes",
        "Vaccines",
        "COVID-19"
      ]
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer",
      "company": "Pfizer",
      "category": "FDA Approval",
      "summary": "Pfizer’s BRAFTOVI® Regimen with Additional Chemotherapy Backbone Increased Response Rates for Certain Patients with Metastatic Colorectal Cancer Anonymous (not verified) Sat, 01/10/2026 - 10:00 Pfizer...",
      "publishedDate": "Sat, 10 Jan 2026 15:00:00 +0000",
      "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizers-braftovir-regimen-additional-chemotherapy-backbone",
      "tags": [
        "Oncology",
        "Cardiovascular",
        "Diabetes"
      ]
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference",
      "company": "Pfizer",
      "category": "FDA Approval",
      "summary": "Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference Anonymous (not verified) Mon, 01/05/2026 - 10:00 Pfizer Press release Financial Finance View pdf copy ...",
      "publishedDate": "Mon, 05 Jan 2026 15:00:00 +0000",
      "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-pfizer-26",
      "tags": [
        "Vaccines",
        "COVID-19",
        "Digital Health"
      ]
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts",
      "company": "Pfizer",
      "category": "FDA Approval",
      "summary": "Pfizer Invites Public to View and Listen to Webcast of February 3 Conference Call with Analysts Anonymous (not verified) Thu, 12/18/2025 - 10:00 Pfizer Press release Financial Finance View pdf copy Co...",
      "publishedDate": "Thu, 18 Dec 2025 15:00:00 +0000",
      "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-invites-public-view-and-listen-webcast-february-3",
      "tags": [
        "Vaccines",
        "COVID-19",
        "Digital Health"
      ]
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility",
      "company": "Pfizer",
      "category": "FDA Approval",
      "summary": "PADCEV™ Plus Keytruda® Significantly Improves Survival for Patients with Muscle-Invasive Bladder Cancer Regardless of Cisplatin Eligibility kimkevin Tue, 12/16/2025 - 15:27 Pfizer Press release Resear...",
      "publishedDate": "Tue, 16 Dec 2025 20:27:55 +0000",
      "url": "https://www.pfizer.com/news/press-release/press-release-detail/padcevtm-plus-keytrudar-significantly-improves-survival",
      "tags": [
        "Oncology",
        "Diabetes",
        "COVID-19"
      ]
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance",
      "company": "Pfizer",
      "category": "FDA Approval",
      "summary": "Pfizer Reaffirms Full-Year 2025 EPS Guidance and Provides Full-Year 2026 Guidance Anonymous (not verified) Tue, 12/16/2025 - 06:45 Pfizer Press release View pdf copy Copy to clipboard Open in tab .q4d...",
      "publishedDate": "Tue, 16 Dec 2025 11:45:00 +0000",
      "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-reaffirms-full-year-2025-eps-guidance-and-provides",
      "tags": [
        "Vaccines",
        "COVID-19",
        "Biosimilar"
      ]
    },
    {
      "id": "aHR0cHM6Ly93d3cu",
      "title": "Pfizer Declares First-Quarter 2026 Dividend",
      "company": "Pfizer",
      "category": "Clinical Trial",
      "summary": "Pfizer Declares First-Quarter 2026 Dividend Anonymous (not verified) Fri, 12/12/2025 - 12:00 Pfizer Press release Financial Finance View pdf copy Copy to clipboard Open in tab .q4default .bwalignc { t...",
      "publishedDate": "Fri, 12 Dec 2025 17:00:00 +0000",
      "url": "https://www.pfizer.com/news/press-release/press-release-detail/pfizer-declares-first-quarter-2026-dividend",
      "tags": [
        "Vaccines",
        "Digital Health"
      ]
    }
  ]
}